CheckMyStock - Developed By GMS Ahimsa

Novartis AG (NVS)

$115.30 +1.56 (0.00%)

Financial Ratios

Book Value per Share (BVPS)
$21.64
(Alpha Vantage)
Net asset value per share of common stock
Debt-to-Equity Ratio
1.32
(Alpha Vantage)
Measures financial leverage and company risk
Return on Invested Capital (ROIC)
20.58%
(Alpha Vantage)
Efficiency of capital allocation for generating returns
Price-to-Earnings Ratio (P/E)
19.48
(Financial Modeling Prep (calculated))
Shows how much investors are willing to pay per dollar of earnings

Company Information

Company Name
Novartis AG
Stock Ticker
NVS
Market Cap
$223,994,478,566
52 Week Range
96.06-124.83
Price
$115.30
Dividend Yield
3.994
About Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.